key: cord-1056146-s5w9ximu authors: Matic, N.; Lawson, T.; Ritchie, G.; Stefanovic, A.; Leung, V.; Champagne, S.; Romney, M. G.; Lowe, C. F. title: Automated molecular testing of saliva for SARS-CoV-2 detection date: 2020-08-14 journal: nan DOI: 10.1101/2020.08.11.20170613 sha: 4686d8e2199409d1638a441b3ae9a3dda0999561 doc_id: 1056146 cord_uid: s5w9ximu Introduction: With surging global demand for increased SARS-CoV-2 testing capacity, clinical laboratories seek automated, high-throughput molecular solutions, particularly for specimen types which do not rely upon supply of specialized collection devices or viral transport media (VTM). Saliva was evaluated as a diagnostic specimen for SARS-CoV-2 using the cobas SARS-CoV-2 Test on the cobas 6800 instrument. Methods: Saliva specimens submitted from various patient populations under investigation for COVID-19 from March-July 2020 were processed in the laboratory with sterile phosphate-buffered saline in a 1:2 dilution and vortexed with glass beads. The processed saliva samples were tested using a commercial assay for detection of the SARS-CoV-2 E gene (LightMix) in comparison to the cobas SARS-CoV-2 Test. Results: 22/64 (34.4%) of the saliva samples were positive for SARS-CoV-2. Positive and negative concordance between the LightMix and cobas assays were 100%. There was no cross-contamination of samples observed on the cobas 6800. The overall invalid rate for saliva on the cobas 6800 (1/128, 0.78%) was similar to the baseline invalid rate observed for nasopharyngeal swabs/VTM and plasma samples. Conclusions: Saliva is a feasible specimen type for SARS-CoV-2 testing on the cobas 6800, with potential to improve turnaround time and enhance testing capacity. The global public health response to the COVID-19 pandemic highlighted the critical need for 25 diagnostic testing which is sustainable, practical, rapid and scalable(1). With an increasing 26 worldwide demand for SARS-CoV-2 molecular testing, supply-chain issues for high-quality, 27 flocked nasopharyngeal (NP) swabs have created significant challenges for testing capacity in 28 clinical and public health laboratories. Alternate specimen types, such as saliva, have been 29 reported in some studies to have nearly comparable sensitivity to nasopharyngeal swabs for the 30 detection of SARS-CoV-2, and may be an appropriate supplemental or alternate diagnostic 31 specimen (2) (3) (4) . Although a variety of methods for saliva collection have been described (2, 5, 6), 32 we have previously shown the utility of testing saliva in the absence of transport media, which 33 enables a simple collection technique that avoids the introduction of potential inhibitors(7, 8) and 34 dependence on supply of specialized saliva collection devices. In addition to potentially obviating supply shortages, saliva has been increasingly described as a 36 useful sample for the diagnosis of COVID-19 to overcome certain pre-analytical collection 37 challenges. Flocked NP swabs have been the preferred specimen type due to established 38 sensitivity, but may occasionally result in false-negative test results due to poor specimen 39 collection quality (9) or timing of testing relative to symptom onset(10-12). Lower respiratory 40 tract specimens such as a bronchoalveolar lavage are often obtained from severely ill patients, 41 but require aerosol-generating medical procedures and thus have the potential for aerosolization 42 and transmission of SARS-CoV-2. Furthermore, only a minority of patients with COVID-19 are 43 able to produce expectorated sputum(13). Saliva is a convenient alternate sample to collect for 44 SARS-CoV-2 detection, particularly for patients with high clinical suspicion for COVID-19 but In our evaluation of the cobas® 6800 for saliva testing, we demonstrated complete concordance 88 in comparison to the LightMix® assay, which is the current assay utilized in our laboratory for 89 clinical testing of specimens other than NP swabs such as saliva. Previous studies have evaluated the feasibility of saliva for SARS-CoV-2 detection on 91 commercial instruments such as the Cepheid GeneXpert® System(16) and cobas® 8800(12). However, there are technical challenges associated with processing saliva for automated, high-93 throughput testing. As a highly viscous sample compared to viral transport media, there is 94 potential for pipetting errors or instrument contamination. In our laboratory, saliva is pre-95 processed with sterile PBS and glass beads in order to decrease the viscosity of the sample. The Due to limited remnant sample volume in some cases, five of the twenty-two saliva samples 113 positive for SARS-CoV-2 (22.7%) underwent additional dilution with sterile PBS in order to test 114 on the cobas® 6800. The Ct values in these cases cannot be directly compared to those from the 115 LightMix® assay as a measure of assay performance; however, the dilution factor in these cases (1:3 to 1:5) would have had a negligible effect on the Ct values, and the aim of this study was to 117 assess the technical feasibility of saliva samples for automated, high-throughput SARS-CoV-2 118 testing on the cobas® 6800. Transitioning to an automated platform for saliva testing is critical for enhancing SARS-CoV-2 120 testing capacity, particularly in preparation for a potential resurgence of COVID-19 cases or 121 mass testing of defined populations. Automated testing reduces errors in the pre-analytical and 122 post-analytical phases, and improves turnaround time by enabling saliva to be processed on 123 multiple runs per day (including overnight testing). Our evaluation confirmed the feasibility of 124 saliva as a suitable specimen type for SARS-CoV-2 testing on the cobas® 6800 platform. WHO. 2020. Laboratory testing for 2019 novel coronavirus Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum 145 antibody responses during infection by SARS-CoV-2: an observational cohort study Sensitivity of nasopharyngeal swabs and 150 saliva for the detection of severe acute respiratory syndrome coronavirus Saliva as a non-153 invasive specimen for detection of SARS-CoV-2 Saliva is more 161 sensitive for SARS-CoV-2 detection in COVID-19 patients than nasopharyngeal swabs SALIVA IS 165 A RELIABLE TOOL TO DETECT SARS-CoV-2 Comparison of the efficiency of different cell lysis 167 methods and different commercial methods for RNA extraction from Candida albicans 168 stored in RNAlater Inappropriateness of RNAlater to preserve Caenorhabditis elegans for RNA extraction Suboptimal 174 biological sampling as a probable cause of false-negative COVID-19 diagnostic test 175 results Virological assessment of hospitalized 179 patients with COVID-2019 Temporal dynamics in viral shedding and transmissibility of 183 COVID-19 Clinical evaluation of 186 self-collected saliva by RT-qPCR, direct RT-qPCR, RT-LAMP, and a rapid antigen test to 187 diagnose COVID-19 Elsevier has created a 191 COVID-19 resource centre with free information in English and Mandarin on the novel 192 coronavirus COVID-research that is available on the COVID-19 resource centre -193 including this ScienceDirect Clinical characteris Journal -2010 -New engla nd journal Interpreting a covid-19 test result Saliva as an Alternate Specimen Source for Detection of SARS-CoV-2 Symptomatic Patients Using Cepheid Xpert Xpress SARS-CoV-2 No significant difference in median cycle threshold (Ct) values for the Envelope (E) gene was observed in saliva samples positive for SARS-CoV-2, using the LightMix® ) and the 208 cobas® SARS-CoV-2 Test 127 We are grateful to our medical laboratory technologists who are highly committed to patient care 128 and laboratory quality improvement.